References
- Schwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: Histologic characteristics, prognostic factors and systemic treatment strategies. Exper Hematol Oncol. 2013; 2: 31.
- Ostad SN, Parsa M. Mehmet Gunduz. Breast cancer – Focusing tumor microenvironment, stem cells and metastasis. Breast cancer from molecular point of view: Pathogenesis and biomarkers . 2011. Available from: http://www.intechopen.com/books/breast-cancer-focusing-tumor-microenvironment-stem-cells-andmetastasis/breast-cancer-from-molecular-point-of-view-pathogenesis-and-biomarkers [cited 14 December 2011]..
- DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics 2013. CA Cancer J Clin. 2014; 64(1): 52–62.
- Fritz A, Percy C, Jack A, Solin LH. International classification of diseases of oncology. 2000; 3rd edn, Geneva: World Health Organization.
- Al Sayed AD, EL Weshi AN, Tulbah AM, Rahal MM, Ezzat AA. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol. 2006; 45: 188–95.
- Nowara E, Drosik A, Samborska-Plewicka M, Nowara EM, Stanek-Widera A. Metaplastic breast carcinomas-analysis of prognostic factors in a case studies. Contemp Oncol. 2014; 18(2): 116–19.
- Moroney JW, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, etal. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012; 18: 5796–805.
- Agarwal R, Koenig K, Rohren E, Subbiah V. Combined antiangiogenic and mammalian target of rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutation. J Breast Cancer. 2014; 17(3): 287–90.